Summary

This article discusses results of a pre-defined subgroup analysis from the bosentan for inoperable chronic thromboembolic pulmonary hypertension [BENEFiT] trial. The BENEFiT study is the first double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of bosentan for patients with inoperable chronic thromboembolic pulmonary hypertension, one of the leading causes of pulmonary arterial hypertension.